Compugen grants 100,000 options to director

Compugen Ltd reported that director Anat Cohen-Dayag received a grant of 100,000 share options to purchase Ordinary Shares at an exercise price of $2.2600 per share.

Accepted by SEC EDGAR 07/30/2026 - 04:09 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Compugen Ltd reported that director Anat Cohen-Dayag received a grant of 100,000 share options to purchase Ordinary Shares at an exercise price of $2.2600 per share. The option expires on 2036-07-29 and vests 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments, subject to continued service. Following this award, the reported derivative holdings from this grant total 100,000 options.

Insider Trade Summary

Grant/Award: 100,000 shares

Grant/Award 1 txn

Insider Cohen-Dayag Anat

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Share Option (right to buy) F1	100,000	$0.00	$0.00

Holdings After Transaction: Share Option (right to buy) — 100,000 contracts (Direct)

Footnotes (1)

1. F1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Options granted: 100000.0000 options Exercise price: 2.2600 per share Expiration date: 2036-07-29 +1 more

4 metrics

Options granted 100000.0000 options Share Option (right to buy) grant to Anat Cohen-Dayag

Exercise price 2.2600 per share Exercise price for options over Ordinary Shares

Expiration date 2036-07-29 Option expiration for Anat Cohen-Dayag grant

Initial vesting 25% Vests 25% on September 30, 2027, subject to continued service

Key Terms

Share Option (right to buy), exercise price, vesting, Ordinary Shares

4 terms

Share Option (right to buy) financial

"security_title is reported as "Share Option (right to buy)""

exercise price financial

"conversion_or_exercise_price is listed as the exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"This option vests 25% on September 30, 2027, and the remainder vests"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Ordinary Shares financial

"underlying_security_title is given as Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Compugen (CGEN) report for Anat Cohen-Dayag?

Compugen reported that director Anat Cohen-Dayag received a grant of 100,000 share options to buy Ordinary Shares. The options carry a $2.2600 exercise price and expire on 2036-07-29, reflecting equity-based compensation rather than a market share sale.

What is the exercise price of the new options granted at Compugen (CGEN)?

The options granted to Anat Cohen-Dayag have an exercise price of $2.2600 per share. Each option allows the purchase of one Ordinary Share at this price until 2036-07-29, subject to the vesting schedule and continued service conditions described in the grant terms.

How many share options did Anat Cohen-Dayag receive from Compugen (CGEN)?

Anat Cohen-Dayag received 100,000 share options over Compugen Ordinary Shares. These options vest over time and, once vested and exercised at $2.2600 per share, could convert into up to 100,000 Ordinary Shares if held through their 2036-07-29 expiration date.

What is the vesting schedule for the new Compugen (CGEN) options grant?

The option vests 25% on September 30, 2027, with the remaining 75% vesting in 12 equal quarterly installments thereafter. Vesting is subject to Anat Cohen-Dayag’s continued service to Compugen, meaning unvested portions depend on ongoing service with the company.

When do the newly granted Compugen (CGEN) options to Anat Cohen-Dayag expire?

The share options granted to Anat Cohen-Dayag expire on 2036-07-29. She may exercise vested portions at $2.2600 per share any time before that date, in accordance with the option agreement and the stated vesting and service conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen-Dayag Anat

(Last) (First) (Middle)

C/O COMPUGEN LTD.

26 HAROKMIM STREET

(Street)

HOLON 5885849

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
COMPUGEN LTD [ CGEN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol
[CGEN]

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (right to buy)	$2.26	07/29/2026		A		100,000		(1)	07/29/2036	Ordinary Shares	100,000	$0	100,000	D

Explanation of Responses:

1. This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Anat Cohen- Dayag	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)